Vir Biotechnology Catapults 58% On Promising Results In Cancer …
Jan 8, 2025 · Vir Biotechnology (VIR) announced promising results Wednesday for a pair of experimental cancer treatments. Vir stock catapulted by double digits. The company's drugs are T-cell engagers. These...
Vir Biotechnology, Inc. - News
Jan 8, 2025 · IR Contact. Vir Biotechnology, Inc. 1800 Owens St., Suite 900 San Francisco, CA 94158. contact us by phone 415-906-4324 [email protected]. Follow us. opens in a new window
Vir Biotechnology, Inc. (VIR) Latest Stock News & Headlines
Get the latest Vir Biotechnology, Inc. (VIR) stock news and headlines to help you in your trading and investing decisions.
Vir Biotechnology, Inc. (VIR) Stock Price, News, Quote & History ...
Find the latest Vir Biotechnology, Inc. (VIR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Vir Biotechnology Receives FDA Breakthrough Therapy …
SAN FRANCISCO, December 12, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough...
Vir Biotechnology, Inc. - Vir Biotechnology Completes …
Mar 5, 2024 · SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier ...
Vir Lays Off 25% of Staff, Abandons Most Virus Work and ... - BioSpace
Aug 2, 2024 · As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.
Vir Biotechnology Receives Buy Rating: Promising TCE Programs …
Jan 15, 2025 · Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA.
Vir Biotechnology, Inc. - Vir Biotechnology Receives FDA …
Dec 12, 2024 · SAN FRANCISCO-- (BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD).
Vir goes Grinch, eliminating 75 posts and shuttering 2 US sites
Dec 14, 2023 · Vir Biotechnology has delivered unseasonably gloomy news to its employees, outlining plans to eliminate 75 positions and shutter two U.S. facilities to save more than $40 million a year.
- Some results have been removed